Jordan Lye/Moment via Getty Images Topline Summary Atara Biotherapeutics (NASDAQ:ATRA) is a commercial-stage biotech focused on the development and commercialization of cell therapies for patients with Epstein-Barr virus infection associated diseases and cancer. While they had a prominent trial failure late last year, they are generating revenues and improving their cash runway all the time. I'm rating this a buy because there is a lot of potential for valuation appreciation if they can remove some of t ...

 First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File CASTRES, France and THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transfo ...

THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal Phase 3 ALLELE study of ta ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registere ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Market LLC Indicate by check mark whether the Registrant (1) has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Market LLC Indicate by check mark whether the Registrant (1) has filed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Market LLC Indicate by check mark whether the Registrant (1) has file ...

INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...

INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...